**Table S3**: Prostate cancer (PCa) risk profiles among Black men and Non-Hispanic White (NHW) men diagnosed with first primary invasive PCa between 2004 and 2013 in California, using 3 risk categorizations (prostate specific antigen [PSA]1, Gleason score [GS]2, and clinical stage3), fully adjusted models● stratified by PSA1, GS2, and stage3

|  |  |
| --- | --- |
|   | Outcome = high PSA1 |
|   | Low GS2 |   | High GS2 |
|   | Low (n) | High (n) | OR | (95% CI) |   | Low (n) | High (n) | OR | (95% CI) |
| Race |   |   |   |  |   |   |   |   |  |
|  NHW men | 98,882 | 5,938 | 1.00 | (Reference) |   | 14,567 | 6,786 | 1.00 | (Reference) |
|  Black men | 15,363 | 1,738 | 1.76 | (1.66-1.87) |   | 1,964 | 1,665 | 1.55 | (1.44-1.68) |
|   | Low stage3 |   | High stage3 |
|   | Low (n) | High (n) | OR | (95% CI) |   | Low (n) | High (n) | OR | (95% CI) |
| Race |   |   |   |  |   |   |   |   |  |
|  NHW men | 107,927 | 7,182 | 1.00 | (Reference) |   | 7,651 | 6,780 | 1.00 | (Reference) |
|  Black men | 16,568 | 2,003 | 1.80 | (1.70-1.90) |   | 995 | 1,664 | 1.59 | (1.45-1.75) |
|   | Low GS2 and low stage3 |   | High GS2 and high stage3 |
|   | Low (n) | High (n) | OR | (95% CI) |   | Low (n) | High (n) | OR | (95% CI) |
| Race |   |   |   |  |   |   |   |   |  |
|  NHW men | 93,583 | 4,337 | 1.00 | (Reference) |   | 3,185 | 3,980 | 1.00 | (Reference) |
|  Black men | 14,563 | 1,281 | 1.82 | (1.69-1.95) |   | 339 | 926 | 1.80 | (1.56-2.07) |
|   | Outcome = high Gleason score2 |
|   | Low PSA1 |   | High PSA1 |
|   | Low (n) | High (n) | OR | (95% CI) |   | Low (n) | High (n) | OR | (95% CI) |
| Race |   |   |   |  |   |   |   |   |  |
|  NHW men | 98,882 | 14,567 | 1.00 | (Reference) |   | 5,938 | 6,786 | 1.00 | (Reference) |
|  Black men | 15,363 | 1,964 | 1.00 | (0.95-1.05) |   | 1,738 | 1,665 | 0.86 | (0.79-0.93) |
|   | Low stage3 |   | High stage3 |
|   | Low (n) | High (n) | OR | (95% CI) |   | Low (n) | High (n) | OR | (95% CI) |
| Race |   |   |   |  |   |   |   |   |  |
|  NHW men | 105,776 | 14,907 | 1.00 | (Reference) |   | 6,721 | 7,840 | 1.00 | (Reference) |
|  Black men | 16,725 | 2,408 | 1.18 | (1.12-1.26) |   | 1,233 | 1,383 | 0.97 | (0.88-1.06) |
|   | Low PSA1 and low stage3 |   | High PSA1 and high stage3 |
|   | Low (n) | High (n) | OR | (95% CI) |   | Low (n) | High (n) | OR | (95% CI) |
| Race |   |   |   |  |   |   |   |   |  |
|  NHW men | 93,583 | 11,190 | 1.00 | (Reference) |   | 1,438 | 3,980 | 1.00 | (Reference) |
|  Black men | 14,563 | 1,602 | 1.07 | (1.00-1.13) |   | 392 | 926 | 0.86 | (0.75-1.00) |

**Table S3 continued.**

|  |  |
| --- | --- |
|   | Outcome = high stage3 |
|   | Low PSA1 |   | High PSA1 |
|   | Low (n) | High (n) | OR | (95% CI) |   | Low (n) | High (n) | OR | (95% CI) |
| Race |   |   |   |  |   |   |   |   |  |
|  NHW men | 107,927 | 7,651 | 1.00 | (Reference) |   | 7,182 | 6,780 | 1.00 | (Reference) |
|  Black men | 16,568 | 995 | 0.90 | (0.84-0.97) |   | 2,003 | 1,664 | 0.81 | (0.75-0.87) |
|   | Low GS2 |   | High GS2 |
|   | Low (n) | High (n) | OR | (95% CI) |   | Low (n) | High (n) | OR | (95% CI) |
| Race |   |   |   |  |   |   |   |   |  |
|  NHW men | 105,776 | 6,721 | 1.00 | (Reference) |   | 14,907 | 7,840 | 1.00 | (Reference) |
|  Black men | 16,725 | 1,233 | 1.16 | (1.08-1.24) |   | 2,408 | 1,383 | 0.98 | (0.90-1.05) |
|   | Low PSA1 and low GS2 |   | High PSA1 and high GS2 |
|   | Low (n) | High (n) | OR | (95% CI) |   | Low (n) | High (n) | OR | (95% CI) |
| Race |   |   |   |  |   |   |   |   |  |
|  NHW men | 93,583 | 3,988 | 1.00 | (Reference) |   | 2,613 | 3,980 | 1.00 | (Reference) |
|  Black men | 14,563 | 607 | 1.01 | (0.92-1.11) |   | 670 | 926 | 0.81 | (0.71-0.91) |
| ●All models adjusted for age at diagnosis, year of diagnosis, marital status, insurance type, and neighborhood socioeconomic status (nSES) |
| 1 PSA risk category low (≤20 ng/ mL) vs. high (>20 ng/ mL) |
| 2 GS risk category low (<8) vs. high (8+) |
| 3 Stage risk categories low (N0, M0, and <T2b) and high (N1, M1, and/ or T2b+) |